TLR4-IN-C34

TLR4-IN-C34
Identifiers
	IUPAC name [(2R,3S,4R,5R,6S)-5-acetamido-3,4-diacetyloxy-6-propan-2-yloxyoxan-2-yl]methyl acetate;
CAS Number	40592-88-9;
PubChem CID	91691128;
ChemSpider	34500445;
ChEMBL	ChEMBL4303607;
CompTox Dashboard (EPA)	DTXSID001336698 ;
Chemical and physical data
Formula	C17H27NO9
Molar mass	389.401 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC(=O)C)OC(=O)C)OC(=O)C)NC(=O)C;
	InChI InChI=1S/C17H27NO9/c1-8(2)24-17-14(18-9(3)19)16(26-12(6)22)15(25-11(5)21)13(27-17)7-23-10(4)20/h8,13-17H,7H2,1-6H3,(H,18,19)/t13-,14-,15-,16-,17+/m1/s1; Key:KMIQMFHPUJUDMC-HHARLNAUSA-N;

TLR4-IN-C34 (or C34) is a drug which acts as a potent and selective antagonist of Toll-like receptor 4 (TLR4). In animal studies it blocks TLR4-mediated cytokine release and has antiinflammatory effects.^[1]^[2]^[3]^[4]^[5]

References

^ Adegoke EO, Adeniran SO, Zeng Y, Wang X, Wang H, Wang C, et al. (June 2019). "Pharmacological inhibition of TLR4/NF-κB with TLR4-IN-C34 attenuated microcystin-leucine arginine toxicity in bovine Sertoli cells". Journal of Applied Toxicology. 39 (6): 832–843. doi:10.1002/jat.3771. PMID 30671980. S2CID 58948493.
^ Lee TH, Park D, Kim YJ, Lee I, Kim S, Oh CT, et al. (April 2020). "Lactobacillus salivarius BP121 prevents cisplatin‑induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p‑cresol sulfate via alleviating dysbiosis". International Journal of Molecular Medicine. 45 (4): 1130–1140. doi:10.3892/ijmm.2020.4495. PMC 7053870. PMID 32124946.
^ Sivak KV, Stosman KI, Rassokha TA, Aleksandrov AG, Kuzmich NN, Orshanskaya YR, et al. (October 2020). "The Effect of TLR4 Blockade on Some Indicators of Systemic Inflammatory Response to Proteus mirabilis LPS in Rats". Bulletin of Experimental Biology and Medicine. 169 (6): 795–797. doi:10.1007/s10517-020-04981-9. PMID 33098506. S2CID 225058037.
^ Zhang SS, Liu M, Liu DN, Yang YL, Du GH, Wang YH (April 2022). "TLR4-IN-C34 Inhibits Lipopolysaccharide-Stimulated Inflammatory Responses via Downregulating TLR4/MyD88/NF-κB/NLRP3 Signaling Pathway and Reducing ROS Generation in BV2 Cells". Inflammation. 45 (2): 838–850. doi:10.1007/s10753-021-01588-8. PMID 34727285. S2CID 241108525.
^ Abdelsalam HM, Helal MG, Abu-Elsaad NM (November 2022). "TLR4-IN-C34 protects against acute kidney injury via modulating TLR4/MyD88/NF-κb axis, MAPK, and apoptosis". Iranian Journal of Basic Medical Sciences. 25 (11): 1334–1340. PMC 9699956. PMID 36474570.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Adegoke EO, Adeniran SO, Zeng Y, Wang X, Wang H, Wang C, et al. (June 2019). "Pharmacological inhibition of TLR4/NF-κB with TLR4-IN-C34 attenuated microcystin-leucine arginine toxicity in bovine Sertoli cells". Journal of Applied Toxicology. 39 (6): 832–843. doi:10.1002/jat.3771. PMID 30671980. S2CID 58948493.

[2] Lee TH, Park D, Kim YJ, Lee I, Kim S, Oh CT, et al. (April 2020). "Lactobacillus salivarius BP121 prevents cisplatin‑induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p‑cresol sulfate via alleviating dysbiosis". International Journal of Molecular Medicine. 45 (4): 1130–1140. doi:10.3892/ijmm.2020.4495. PMC 7053870. PMID 32124946.

[3] Sivak KV, Stosman KI, Rassokha TA, Aleksandrov AG, Kuzmich NN, Orshanskaya YR, et al. (October 2020). "The Effect of TLR4 Blockade on Some Indicators of Systemic Inflammatory Response to Proteus mirabilis LPS in Rats". Bulletin of Experimental Biology and Medicine. 169 (6): 795–797. doi:10.1007/s10517-020-04981-9. PMID 33098506. S2CID 225058037.

[4] Zhang SS, Liu M, Liu DN, Yang YL, Du GH, Wang YH (April 2022). "TLR4-IN-C34 Inhibits Lipopolysaccharide-Stimulated Inflammatory Responses via Downregulating TLR4/MyD88/NF-κB/NLRP3 Signaling Pathway and Reducing ROS Generation in BV2 Cells". Inflammation. 45 (2): 838–850. doi:10.1007/s10753-021-01588-8. PMID 34727285. S2CID 241108525.

[5] Abdelsalam HM, Helal MG, Abu-Elsaad NM (November 2022). "TLR4-IN-C34 protects against acute kidney injury via modulating TLR4/MyD88/NF-κb axis, MAPK, and apoptosis". Iranian Journal of Basic Medical Sciences. 25 (11): 1334–1340. PMC 9699956. PMID 36474570.

[1]

[2]

[3]

[4]

[5]

See also

References